Group 1 - Birkenstock (BIRK) shares have increased by 9.6% over the past four weeks, closing at $55.05, with a mean price target of $68.88 indicating a potential upside of 25.1% [1] - The average of 17 short-term price targets ranges from a low of $57 to a high of $81, with a standard deviation of $7.34, suggesting a relatively high agreement among analysts [2] - Analysts have shown increasing optimism regarding BIRK's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for BIRK's current year earnings has risen by 3.4% over the past month, with seven estimates increasing and two decreasing [12] - BIRK holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [13]

Shares of Perrigo (PRGO) have gained 8.8% over the past four weeks to close the last trading session at $26.91, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $34.25 indicates a potential upside of 27.3%.The mean estimate comprises four short-term price targets with a standard deviation of $6.95. While the lowest estimate of $27 indicates a 0.3% increase from the current price ...

Shares of The RealReal (REAL) have gained 3% over the past four weeks to close the last trading session at $5.43, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $10.10 indicates a potential upside of 86%.The average comprises five short-term price targets ranging from a low of $7 to a high of $15, with a standard deviation of $3.09. While the lowest estimate indicates an increa ...

Core Viewpoint - Accel Entertainment (ACEL) shares have increased by 4.1% recently, with analysts suggesting a potential upside of 36.7% based on a mean price target of $15.67 [1][11]. Price Targets and Analyst Estimates - The mean price target consists of three short-term estimates with a standard deviation of $0.58, indicating a consensus among analysts [2]. - The lowest estimate is $15, suggesting a 30.9% increase, while the highest estimate is $16, indicating a 39.6% increase from the current price [2]. - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Market Sentiment - Analysts are optimistic about ACEL's earnings prospects, as indicated by upward revisions in EPS estimates, which have shown a strong correlation with stock price movements [11]. - Over the past 30 days, two earnings estimates have been revised upward, leading to an 8% increase in the Zacks Consensus Estimate [12]. - ACEL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13].

Shares of West Pharmaceutical Services (WST) have gained 7.3% over the past four weeks to close the last trading session at $216.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $284 indicates a potential upside of 31.1%.The average comprises 10 short-term price targets ranging from a low of $245 to a high of $355, with a standard deviation of $34.94. While the lowest estimat ...

Core Viewpoint - AtriCure (ATRC) shows potential for significant upside, with a mean price target of $49.89 indicating a 54.7% increase from its current price of $32.25 [1] Price Targets and Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $6.37, suggesting variability among analysts [2] - The lowest estimate of $40 indicates a 24% increase, while the highest estimate suggests an 86.1% surge to $60 [2] - Analysts' consensus on price targets should be approached with caution, as their reliability has been questioned [3][7] Earnings Estimates and Analyst Agreement - Analysts are optimistic about AtriCure's earnings, with a positive trend in earnings estimate revisions indicating potential stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 25.1%, with four estimates moving higher and no negative revisions [12] - AtriCure holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding price movement direction [9] - While price targets should not be the sole basis for investment decisions, they can provide a starting point for further research [10]

Shares of Intellia Therapeutics, Inc. (NTLA) have gained 14.9% over the past four weeks to close the last trading session at $7.88, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $40.08 indicates a potential upside of 408.6%.The mean estimate comprises 25 short-term price targets with a standard deviation of $26.66. While the lowest estimate of $9 indicates a 14.2% increase fro ...

Shares of NovoCure (NVCR) have gained 8% over the past four weeks to close the last trading session at $17.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.14 indicates a potential upside of 105.5%.The mean estimate comprises seven short-term price targets with a standard deviation of $6.74. While the lowest estimate of $27 indicates a 57.9% increase from the current pric ...

Clearfield (CLFD) closed the last trading session at $36.36, gaining 37.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $46 indicates a 26.5% upside potential.The average comprises four short-term price targets ranging from a low of $44 to a high of $50, with a standard deviation of $2.71. While the lowest estimate indicates an increase of 21% from the current price level, the m ...

Shares of Easterly Government Properties (DEA) have gained 0.1% over the past four weeks to close the last trading session at $20.92, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $28.25 indicates a potential upside of 35%.The mean estimate comprises five short-term price targets with a standard deviation of $3.26. While the lowest estimate of $23.75 indicates a 13.5% increase ...